DESTINY-Breast03 Phase 3 Study Results

Conclusions Trastuzumab-deruxtecan was active in patients with HER2-positive breast cancer brain metastases ◉ TUXEDO-1 met its primary endpoint Response rate (intention-to-treat population) 73.3% Comparable extra- and intracranial response rates Prolonged disease control ■ No new safety signals were observed ■ Quality-of-life was maintained over the treatment period ■ Adds to the growing body of evidence that systemic therapy is feasible in HER2-positive breast cancer with CNS metastasis Supports further investigation of ADCs in the context of secondary CNS malignancies ESMO BC 2022 #165 Mini Oral Daiichi-Sankyo 59

View entire presentation